化苑讲坛
首页 >> 化苑讲坛 >> 正文

234期

Wei Li

作者:  发布:2017-01-06 00:00:00  点击量:

 田纳西大学Wei Li教授

做客第234期化苑讲坛

 

报告题目:Discovery of novel tubulin inhibitors targeting the colchicine binding site for cancer therapy

  人 :Wei Li教授

报告时间:201716日(周五)下午1530

报告地点:化学楼二楼一号会议室

 

报告人简介:

Prof. Li received his PhD degree in Chemistry in 1999 from Columbia University in the City of New York. He is a Professor in his current institution and also serves as the Section Editor for anticancer agents of Current Medicinal Chemistry. His area of research is small molecule drug discovery. He has published over 120 papers, is an inventor of five issued US patents and additional large numbers of patents from other countries, and is a frequent grant reviewer for the US NIH, NSF, and other US Government and State Agencies.

 

报告内容:

Despite the advancements of targeted therapy and immunotherapy, tubulin inhibitors are still the most widely prescribed chemotherapeutic drugs for many types of cancers.  However, efficacies of FDA approved tubulin inhibitors are often limited by multidrug resistance mechanisms such as overexpression of ABC-transporters. They also have poor aqueous solubility and are not orally bioavailable. Dr. Li’s Lab discovered a new generation of tubulin inhibitors that effectively overcome some of these clinical limitations. They are licensed to Veru HealthCare who will start clinical trials in 2017. In this talk, he will describe the efforts in the discovery and development of these new tubulin inhibitors.

 

上一篇:235期
下一篇:233期

版权所有 44118太阳成城集团 - 太阳娱乐官网app下载 COPYRIGHT 2014-2021
通讯地址:湖北省武汉市洪山区珞喻路1037号44118太阳成城集团西一楼208室
邮编:430074
联系电话:027-58868736
学院邮箱:hustchem@hust.edu.cn

  • 微信公众号